Levobetaxolol
Betaxon (levobetaxolol) is a small molecule pharmaceutical. Levobetaxolol was first approved as Betaxon on 2000-02-23. It is used to treat ocular hypertension and open-angle glaucoma in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target beta-2 adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
eye diseases | D005128 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levobetaxolol hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
BETAXON | Alcon Research | N-021114 DISCN | 2000-02-23 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
ocular hypertension | EFO_1001069 | D009798 | H40.0 |
open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | 4 | 2 | 5 | 1 | — | 11 |
Essential hypertension | D000075222 | I10 | 2 | — | — | 3 | 1 | 6 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 3 | — | — | — | — | 3 |
Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LEVOBETAXOLOL |
INN | levobetaxolol |
Description | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. |
Classification | Small molecule |
Drug class | beta-blockers (propranolol type) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1 |
Identifiers
PDB | — |
CAS-ID | 93221-48-8 |
RxCUI | 353497 |
ChEMBL ID | CHEMBL1201274 |
ChEBI ID | 59254 |
PubChem CID | 60657 |
DrugBank | DB00195 |
UNII ID | 75O9XHA4TU (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 49 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
15 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more